Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 174.52 Million SEK | -7.61% |
| 2022 | 190 Million SEK | 13.17% |
| 2021 | 167.9 Million SEK | 52.03% |
| 2020 | 110.44 Million SEK | 59.74% |
| 2019 | 69.13 Million SEK | 34.41% |
| 2018 | 51.43 Million SEK | 48.79% |
| 2017 | 34.57 Million SEK | 54.98% |
| 2016 | 22.3 Million SEK | 15.97% |
| 2015 | 19.23 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 55.4 Million SEK | 24.7% |
| 2024 Q2 | 45.82 Million SEK | -17.29% |
| 2024 Q3 | 42.57 Million SEK | -7.1% |
| 2023 Q2 | 42.9 Million SEK | -2.01% |
| 2023 Q1 | 43.78 Million SEK | -6.91% |
| 2023 Q4 | 44.42 Million SEK | 5.71% |
| 2023 Q3 | 42.02 Million SEK | -2.04% |
| 2023 FY | 175.54 Million SEK | -7.61% |
| 2022 Q1 | 45.05 Million SEK | -11.97% |
| 2022 Q2 | 48.7 Million SEK | 8.12% |
| 2022 FY | 190 Million SEK | 13.17% |
| 2022 Q3 | 49.21 Million SEK | 1.04% |
| 2022 Q4 | 47.03 Million SEK | -4.42% |
| 2021 Q2 | 42.56 Million SEK | 9.23% |
| 2021 FY | 167.9 Million SEK | 52.03% |
| 2021 Q1 | 38.96 Million SEK | 21.89% |
| 2021 Q4 | 51.17 Million SEK | 45.39% |
| 2021 Q3 | 35.19 Million SEK | -17.3% |
| 2020 Q4 | 31.96 Million SEK | 23.0% |
| 2020 FY | 110.44 Million SEK | 59.74% |
| 2020 Q3 | 25.99 Million SEK | -10.18% |
| 2020 Q2 | 28.93 Million SEK | 22.92% |
| 2020 Q1 | 23.54 Million SEK | 22.46% |
| 2019 Q3 | 17.11 Million SEK | 2.2% |
| 2019 Q2 | 16.74 Million SEK | 4.23% |
| 2019 Q4 | 19.22 Million SEK | 12.36% |
| 2019 FY | 69.13 Million SEK | 34.41% |
| 2019 Q1 | 16.06 Million SEK | 12.97% |
| 2018 Q1 | 12.51 Million SEK | 19.99% |
| 2018 Q2 | 13.31 Million SEK | 6.33% |
| 2018 Q3 | 11.39 Million SEK | -14.44% |
| 2018 Q4 | 14.21 Million SEK | 24.83% |
| 2018 FY | 51.43 Million SEK | 48.79% |
| 2017 Q2 | 7.69 Million SEK | 11.91% |
| 2017 Q3 | 9.57 Million SEK | 24.52% |
| 2017 Q4 | 10.43 Million SEK | 8.94% |
| 2017 Q1 | 6.87 Million SEK | -2.86% |
| 2017 FY | 34.57 Million SEK | 54.98% |
| 2016 Q1 | 4.79 Million SEK | 0.0% |
| 2016 FY | 22.3 Million SEK | 15.97% |
| 2016 Q4 | 7.07 Million SEK | 20.49% |
| 2016 Q2 | 4.57 Million SEK | -4.56% |
| 2016 Q3 | 5.87 Million SEK | 28.4% |
| 2015 FY | 19.23 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -110.655% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 71.473% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 71.473% |
| Arcoma AB | 53.25 Million SEK | -227.74% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -3412.336% |
| BICO Group AB (publ) | 2.84 Billion SEK | 93.873% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 17.067% |
| CellaVision AB (publ) | 295.99 Million SEK | 41.036% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -153.196% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -13231.062% |
| C-Rad AB (publ) | 3.8 Million SEK | -4492.842% |
| Duearity AB (publ) | 21.58 Million SEK | -708.562% |
| Dignitana AB (publ) | 74.73 Million SEK | -133.526% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -6364.0% |
| Getinge AB (publ) | 10.75 Billion SEK | 98.378% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -857.443% |
| Iconovo AB (publ) | 63.35 Million SEK | -175.479% |
| Integrum AB (publ) | 90.57 Million SEK | -92.696% |
| Luxbright AB (publ) | 23.09 Million SEK | -655.843% |
| Mentice AB (publ) | 237.06 Million SEK | 26.378% |
| OssDsign AB (publ) | 175.6 Million SEK | 0.611% |
| Paxman AB (publ) | 133.8 Million SEK | -30.439% |
| Promimic AB (publ) | 48.55 Million SEK | -259.466% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -7.478% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -149.411% |
| ScandiDos AB (publ) | 61.03 Million SEK | -185.933% |
| Sectra AB (publ) | 39.06 Million SEK | -346.786% |
| Senzime AB (publ) | 141.51 Million SEK | -23.327% |
| SpectraCure AB (publ) | 12.12 Million SEK | -1339.05% |
| Stille AB | 87.21 Million SEK | -100.103% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 96.865% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 60.418% |